Bexagliflozin Efficacy and Safety Trial (BEST)
A double-blind placebo controlled study to evaluate the effects of bexaglifozin on hemoglobin A1c in patients with Type 2 diabetes and increased risk of cardiovascular adverse events.
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with Type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The study is an event-driven trial. The treatment period will end when the last randomized subject has completed at least 52 weeks of treatment and a total of at least 134 subjects have experienced a cardiac event.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.